Report initial data from the MGTA-145 multiple myeloma clinical trial
Delivered after the deadline (166 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 13 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the first clinical trial in patients with multiple myeloma (initial data expected in mid-2021)”
What we found
Evidence strength A What the grades mean
The company did not report initial data by mid-2021; instead, it announced in August 2021 that final data was expected in Q4, with the results ultimately presented on December 13, 2021.
-
A Magenta Therapeutics, Inc. 8-K filed 2021-08-05
“Enrollment complete for Phase 2 clinical trial evaluating MGTA-145 plus plerixafor in patients with multiple myeloma; final clinical data expected in Q4 2021” ✓ confirmed on the page
-
A Magenta Therapeutics, Inc. 8-K filed 2021-11-04
“Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell mobilization and transplant engraftment using MGTA-145 plus plerixafor in patients with multiple myeloma will be presented as a poster at the 2021 American Society of Hematology ” ✓ confirmed on the page
Market reaction: the shares moved +4.4% against the S&P 500 over the three sessions around the disclosure (4 Aug 2021 to 9 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- MGTA-145 multiple myeloma clinical trial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Magenta Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-DNTH-021635 · Corrections policy